Relative Effectiveness of COVID-19 Vaccine Booster Doses in People Aged 65 and Older-a Retrospective Cohort Study in Türkiye

Overview

Journal Ther Adv Vaccines Immunother

Publisher Sage Publications

Date 2024 Oct 7

PMID 39372967

Authors

Mehmet Akif Sezerol

Alican Sarisaltik

Affiliations

Soon will be listed here.

Abstract

Background: Immunization in the elderly population is critical due to the high frequency of health outcomes related to COVID-19.

Objectives: This study aimed to compare the effectiveness levels of COVID-19 vaccine schedules in preventing SARS-CoV-2 infection in the older adult group who received at least one booster dose.

Design: Retrospective cohort study.

Methods: This study evaluated 8969 adults aged 65 and over in the Sultanbeyli district of İstanbul. COVID-19 vaccination and SARS-CoV-2 polymerase chain reaction testing data between January 14, 2021 and December 2, 2022 were obtained from the National Public Health Management System.

Results: The median age of participants was 71 years. The vaccines were mostly administered as CoronaVac for the first and second doses (81.4% and 82.2%, respectively) and BNT162b2 for the third and fourth doses (61.8% and 73.1%, respectively). Turkovac was administered only in booster doses (third dose 0.6%, fourth dose 4.8%). The adjusted relative vaccine effectiveness (rVE) was found to be 61.8% (95% confidence interval (CI) 51.5-69.9) in two doses of inactivated vaccine and one dose of mRNA vaccine schedule compared to the homolog booster of CoronaVac primary vaccine schedule. In two booster doses receipts, the adjusted rVE was found to be 45.4% (95% CI 13.8-65.4) in three doses of inactivated and one dose mRNA vaccine schedule and 43.0% (95% CI 20.5-59.2) in two doses of inactivated and two doses of mRNA vaccines schedule compared to the two homolog boosters with CoronaVac primary vaccine schedule.

Conclusion: In this study, the effectiveness of the mRNA vaccine as a booster dose was higher than that of the homologous boosters in participants receiving the CoronaVac primary series for those aged 65 and over.

References

Medetalibeyoglu A, Senkal N, Kose M, Catma Y, Bilge Caparali E, Erelel M . Older Adults Hospitalized with Covid-19: Clinical Characteristics and Early Outcomes from a Single Center in Istanbul, Turkey. J Nutr Health Aging. 2020; 24(9):928-937. PMC: 7597420. DOI: 10.1007/s12603-020-1477-2. View

Wan E, Mok A, Yan V, Chan C, Wang B, Lai F . Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med. 2022; 29(8). PMC: 9619717. DOI: 10.1093/jtm/taac119. View

Caglayan D, Suner A, Siyve N, Guzel I, Irmak C, Isik E . An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol. 2022; 94(5):2212-2221. PMC: 9015267. DOI: 10.1002/jmv.27620. View

Buchan S, Chung H, Brown K, Austin P, Fell D, Gubbay J . Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw Open. 2022; 5(9):e2232760. PMC: 9500552. DOI: 10.1001/jamanetworkopen.2022.32760. View

Allen H, Tessier E, Turner C, Anderson C, Blomquist P, Simons D . Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. Epidemiol Infect. 2023; 151:e58. PMC: 10125873. DOI: 10.1017/S0950268823000420. View

Sezerol M, Davun S . COVID-19 Vaccine Booster Dose Acceptance among Older Adults. Vaccines (Basel). 2023; 11(3). PMC: 10056148. DOI: 10.3390/vaccines11030542. View

Ong A, Prasetyo Y, Lagura F, Ramos R, Salazar J, Sigua K . Young adult preference analysis on the attributes of COVID-19 vaccine in the Philippines: A conjoint analysis approach. Public Health Pract (Oxf). 2022; 4:100300. PMC: 9293378. DOI: 10.1016/j.puhip.2022.100300. View

Checcucci E, Piramide F, Pecoraro A, Amparore D, Campi R, Fiori C . The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. Panminerva Med. 2020; 64(1):72-79. DOI: 10.23736/S0031-0808.20.03958-0. View

Uzun O, Akpolat T, Varol A, Turan S, Gokbulut Bektas S, Duru Cetinkaya P . COVID-19: vaccination vs. hospitalization. Infection. 2022; 50(3):747-752. PMC: 8725959. DOI: 10.1007/s15010-021-01751-1. View

10.

Low E, Tok P, Husin M, Suah J, Tng B, Thevananthan T . Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months. JAMA Netw Open. 2022; 5(8):e2226046. PMC: 9366545. DOI: 10.1001/jamanetworkopen.2022.26046. View

11.

Wang G, Yao Y, Wang Y, Gong J, Meng Q, Wang H . Determinants of COVID-19 vaccination status and hesitancy among older adults in China. Nat Med. 2023; 29(3):623-631. PMC: 10285745. DOI: 10.1038/s41591-023-02241-7. View

12.

Stowe J, Andrews N, Kirsebom F, Ramsay M, Lopez Bernal J . Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022; 13(1):5736. PMC: 9523190. DOI: 10.1038/s41467-022-33378-7. View

13.

Abul Y, Leeder C, Gravenstein S . Epidemiology and Clinical Presentation of COVID-19 in Older Adults. Infect Dis Clin North Am. 2023; 37(1):1-26. PMC: 9633621. DOI: 10.1016/j.idc.2022.11.001. View

14.

Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J . Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022; 19(17). PMC: 9517782. DOI: 10.3390/ijerph191710752. View

15.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M . Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369(6499):77-81. PMC: 7202686. DOI: 10.1126/science.abc1932. View

16.

Culpan H, Aydin S, Uygur A, Sayili U, Seker E, Balkan I . Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers. Hum Vaccin Immunother. 2023; 19(3):2275445. PMC: 10653742. DOI: 10.1080/21645515.2023.2275445. View

17.

Park J, Lagniton P, Liu Y, Xu R . mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021; 17(6):1446-1460. PMC: 8071766. DOI: 10.7150/ijbs.59233. View

18.

Jara A, Undurraga E, Zubizarreta J, Gonzalez C, Pizarro A, Acevedo J . Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022; 10(6):e798-e806. PMC: 9034854. DOI: 10.1016/S2214-109X(22)00112-7. View

19.

Sharma O, Sultan A, Ding H, Triggle C . A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020; 11:585354. PMC: 7591699. DOI: 10.3389/fimmu.2020.585354. View